Inventor · disambiguated record
Jason Gary Sagert
Also filed as: SAGERT JASON · SAGERT JASON G · SAGERT JASON GARY
48 granted patents·28 pending applications·1,167 citations·filing 2010–2024
99Inventor score
Files withCYTOMX THERAPEUTICS INC47CRISPR THERAPEUTICS AG16UNIV CALIFORNIA4STAGLIANO NANCY E3CYTOMX THERAPETUICS INC2
Top patents by PatentIndex Score
76 records- 0198US10875913B2Methods of treatment using activatable anti-EGFR antibodiesCYTOMX THERAPEUTICS INC·Filed 2018·Granted Dec 29, 2020·21 cites·40 claims
- 0298US10179817B2Anti-CD71 antibodies, activatable anti-CD71 antibodies, and methods of use thereofCYTOMX THERAPEUTICS INC·Filed 2016·Granted Jan 15, 2019·36 cites·58 claims
- 0398US10118961B2Modified antibody containing the cleavable peptide with the amino acid sequence TGRGPSWVCYTOMX THERAPEUTICS INC·Filed 2016·Granted Nov 6, 2018·34 cites·13 claims
- 0498US10077300B2Activatable binding polypeptides and methods of identification and use thereofUNIV CALIFORNIA·Filed 2015·Granted Sep 18, 2018·42 cites·36 claims
- 0598US10059762B2Anti-EGFR activatable antibodiesCYTOMX THERAPEUTICS INC·Filed 2016·Granted Aug 28, 2018·42 cites·41 claims
- 0698US9644016B2Soluble notch receptor proproteins and methods of use thereofCYTOMX THERAPEUTICS INC·Filed 2015·Granted May 9, 2017·34 cites·28 claims
- 0798US8541203B2Activatable binding polypeptides and methods of identification and use thereofDAUGHERTY PATRICK SEAN·Filed 2012·Granted Sep 24, 2013·73 cites·41 claims
- 0898US8513390B2Modified antibody compositions, methods of making and using thereofSTAGLIANO NANCY E·Filed 2012·Granted Aug 20, 2013·111 cites·137 claims
- 0997US10745481B2Anti-CD166 antibodies, activatable anti-CD166 antibodies, and methods of use thereofCYTOMX THERAPEUTICS INC·Filed 2016·Granted Aug 18, 2020·22 cites·88 claims
- 1097US10709799B2Activatable antibodies that bind epidermal growth factor receptor and methods of use thereofCYTOMX THERAPEUTICS INC·Filed 2018·Granted Jul 14, 2020·10 cites·31 claims
- 1197US9889211B2Activatable antibodies that bind epidermal growth factor receptor and methods of use thereofCYTOMX THERAPEUTICS INC·Filed 2016·Granted Feb 13, 2018·29 cites·52 claims
- 1297US9169321B2Activatable binding polypeptides and methods of identification and use thereofUNIV CALIFORNIA·Filed 2013·Granted Oct 27, 2015·62 cites·41 claims
- 1397US9127053B2Anti-jagged 1/jagged 2 cross-reactive antibodies, activatable anti-jagged antibodies and methods of use thereofCYTOMX THERAPEUTICS INC·Filed 2013·Granted Sep 8, 2015·39 cites·33 claims
- 1497US9120853B2Activatable antibodies that bind epidermal growth factor receptor and methods of use thereofCYTOMX THERAPEUTICS INC·Filed 2013·Granted Sep 1, 2015·52 cites·43 claims
- 1597US8563269B2Modified antibody compositions, methods of making and using thereofSTAGLIANO NANCY E·Filed 2011·Granted Oct 22, 2013·119 cites·38 claims
- 1697US8399219B2Protease activatable interferon alpha proproteinSTAGLIANO NANCY E·Filed 2010·Granted Mar 19, 2013·46 cites·17 claims
- 1796US11459372B2Gene-edited natural killer cellsCRISPR THERAPEUTICS AG·Filed 2021·Granted Oct 4, 2022·3 cites·26 claims
- 1896US10669337B2Bispecific anti-CD3 antibodies, bispecific activatable anti-CD3 antibodies, and methods of using the sameCYTOMX THERAPEUTICS INC·Filed 2015·Granted Jun 2, 2020·31 cites·16 claims
- 1996US9545442B2Activatable antibodies that bind epidermal growth factor receptor and methods of use thereofCYTOMX THERAPEUTICS INC·Filed 2015·Granted Jan 17, 2017·19 cites·57 claims
- 2096US9453078B2Modified antibody compositions, methods of making and using thereofCYTOMX THERAPETUICS INC·Filed 2013·Granted Sep 27, 2016·64 cites·28 claims
- 2196US8993266B2Proproteins activatable interferon alphaCYTOMX THERAPEUTICS INC·Filed 2012·Granted Mar 31, 2015·28 cites·14 claims
- 2296US8518404B2Activatable binding polypeptides and methods of identification and use thereofDAUGHERTY PATRICK·Filed 2012·Granted Aug 27, 2013·105 cites·25 claims
- 2395US11753466B2Anti-CD166 antibodies, activatable anti-CD166 antibodies, and methods of use thereofCYTOMX THERAPEUTICS INC·Filed 2019·Granted Sep 12, 2023·7 cites·64 claims
- 2495US10669339B2Anti-PDL1 antibodies, activatable anti-PDL1 antibodies, and methods of use thereofCYTOMX THERAPEUTICS INC·Filed 2019·Granted Jun 2, 2020·10 cites·44 claims
- 2595US10513549B2Cleavage-activatable interferon-alpha proproteinCYTOMX THERAPEUTICS INC·Filed 2017·Granted Dec 24, 2019·14 cites·11 claims
- 2695US10301380B2Anti-jagged 1/jagged 2 cross-reactive antibodies, activatable anti-jagged antibodies and methods of use thereofCYTOMX THERAPEUTICS INC·Filed 2017·Granted May 28, 2019·17 cites·29 claims
- 2795US10233244B2Anti-ITGA3 antibodies, activatable anti-ITGA3 antibodies, and methods of use thereofCYTOMX THERAPEUTICS INC·Filed 2016·Granted Mar 19, 2019·26 cites·48 claims
- 2895US9487590B2Activatable antibodies that bind interleukin-6 receptor and methods of use thereofCYTOMX THERAPEUTICS INC·Filed 2013·Granted Nov 8, 2016·15 cites·35 claims
- 2994US11267896B2Anti-CD71 antibodies, activatable anti-CD71 antibodies, and methods of use thereofCYTOMX THERAPEUTICS INC·Filed 2018·Granted Mar 8, 2022·10 cites·34 claims
- 3094US11028162B2Methods for manufacturing activatable binding polypeptides comprising matrix metalloprotease cleavable moietiesUNIV CALIFORNIA·Filed 2018·Granted Jun 8, 2021·6 cites·27 claims
- 3194US10336824B2Anti-PDL1 antibodies, activatable anti-PDL1 antibodies, and methods of thereofCYTOMX THERAPEUTICS INC·Filed 2016·Granted Jul 2, 2019·16 cites·48 claims
- 3293US11890354B2Activatable antibodies that bind epidermal growth factor receptor and methods thereofCYTOMX THERAPEUTICS INC·Filed 2020·Granted Feb 6, 2024·2 cites·16 claims
- 3393US9688748B2Anti-jagged 1/jagged 2 cross-reactive antibodies, activatable anti-jagged antibodies and methods of use thereofCYTOMX THERAPEUTICS INC·Filed 2015·Granted Jun 27, 2017·11 cites·39 claims
- 3492US11591381B2Gene-edited natural killer cellsCRISPR THERAPEUTICS AG·Filed 2021·Granted Feb 28, 2023·2 cites·27 claims
- 3591US11046759B2Matrix metalloprotease-cleavable and serine protease-cleavable substrates and methods of use thereofCYTOMX THERAPEUTICS INC·Filed 2016·Granted Jun 29, 2021·4 cites·58 claims
- 3690US12502439B2Activatable antibodies that bind epidermal growth factor receptor and methods of use thereofCYTOMX THERAPEUTICS INC·Filed 2023·Granted Dec 23, 2025·0 cites·20 claims
- 3790US2024228603A1Modified antibody compositions, methods of making and using thereofCYTOMX THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 3888US11926676B2Masked chimeric antigen receptor specific to tyrosine-protein kinase like 7 (PTK7) and immune cells expressing suchCRISPR THERAPEUTICS AG·Filed 2021·Granted Mar 12, 2024·1 cites·30 claims
- 3986US12459999B2Matrix metalloprotease-cleavable and serine protease-cleavable substrates and methods of use thereofCYTOMX THERAPEUTICS INC·Filed 2022·Granted Nov 4, 2025·0 cites·8 claims
- 4085US2023183308A1Proproteins and methods of use thereofCYTOMX THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 4184US10611845B2Activatable antibodies that bind interleukin-6 receptor and methods of use thereofCYTOMX THERAPEUTICS INC·Filed 2016·Granted Apr 7, 2020·2 cites·35 claims
- 4282US11802158B2Bispecific anti-CD3 antibodies, bispecific activatable anti-CD3 antibodies, and methods of using the sameCYTOMX THERAPEUTICS INC·Filed 2020·Granted Oct 31, 2023·1 cites·21 claims
- 4382US11174316B2Anti-PDL1 antibodies, activatable anti-PDL1 antibodies, and methods of use thereofCYTOMX THERAPEUTICS INC·Filed 2019·Granted Nov 16, 2021·1 cites·19 claims
- 4481US2023035290A1Proproteins and methods of use thereofCYTOMX THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 4580US12344655B2Gene-edited natural killer cellsCRISPR THERAPEUTICS AG·Filed 2022·Granted Jul 1, 2025·0 cites·19 claims
- 4679US12209120B2Activatable anti-VEGF scFvUNIV CALIFORNIA·Filed 2021·Granted Jan 28, 2025·0 cites·3 claims
- 4779US11548943B2Matrix metalloprotease-cleavable and serine protease-cleavable substrates and methods of use thereofCYTOMX THERAPEUTICS INC·Filed 2021·Granted Jan 10, 2023·0 cites·9 claims
- 4879US11472875B1Matrix metalloprotease-cleavable and serine protease-cleavable substrates and methods of use thereofCYTOMX THERAPEUTICS INC·Filed 2021·Granted Oct 18, 2022·0 cites·11 claims
- 4978US11548944B2Matrix metalloprotease-cleavable and serine protease-cleavable substrates and methods of use thereofCYTOMX THERAPEUTICS INC·Filed 2021·Granted Jan 10, 2023·0 cites·10 claims
- 5078US2025074965A1Anti-ptk7 immune cell cancer therapyCRISPR THERAPEUTICS AG·Filed 2024·Application pending·0 cites
Showing the top 50 of 76 patent records by PatentIndex Score.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →